Apixaban's effect on blood clotting in newly diagnosed multiple myeloma
Official title: Comparison of the Effects of Prophylactic Administration of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma and Patients Undergoing a Surgery for Total Knee Replacement
Run by Centre Hospitalier Universitaire de Saint Etienne · NCT06474182 · Data updated 2026-11-12
This test sees if apixaban lowers blood clotting more in people with newly diagnosed multiple myeloma than in people taking apixaban after knee replacement.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 1 site (Saint-Etienne) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | September 2027 |
| Study ends | March 2028 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT06474182 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with newly diagnosed multiple myeloma who require apixaban prophylaxis, and adults undergoing total knee replacement who will receive apixaban, who can provide informed consent and attend blood draws.
✕Probably not a fit
Patients on full therapeutic anticoagulation, those with contraindications to apixaban, pregnant or breastfeeding women, or people unable to consent are not eligible and would not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares blood clotting activity and apixaban plasma levels between two groups: patients with de novo multiple myeloma receiving prophylactic apixaban and patients receiving apixaban after total knee replacement. Investigators collect timed blood samples to measure apixaban concentration and thrombin generation (coagulability) assays. The protocol examines whether pharmacokinetic differences in myeloma plasma translate into greater reductions in thrombin generation. Findings may indicate whether thromboprophylaxis dosing or monitoring should be adjusted for multiple myeloma patients.
Why it matters
Potential benefit: If successful, the results could help tailor apixaban thromboprophylaxis to reduce clotting and bleeding risks in multiple myeloma patients.
How similar studies have gone: Prior trials like AVERT have shown apixaban prevents VTE in cancer patients and the APIXABOR ancillary work found higher apixaban peaks in myeloma plasma, but direct pharmacodynamic comparisons of coagulability in myeloma versus surgical patients are novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old, * Signed informed consent, * Patient covered by a social security scheme. * Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban, * Group 2 : patient requiring a surgery for total knee replacement, , with an indication of thromboprophylaxis with Apixaban. Exclusion Criteria: * Curative doses of anticoagulation treatment, * Contra-indication to Apixaban, * Pregnant or breastfeeding woman, * Refusal to sign consent, * Patient under legal protection.
Where it's running
-
CHU de Saint-Etienne
Saint-Etienne, France Recruiting
Study contacts
- Principal investigator: Emilie CHALAYER, MD — CHU de Saint-Etienne
- Study coordinator: Emilie CHALAYER, MD
- Email: emilie.chalayer@chu-st-etienne.fr
- Phone: (0)477822814
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Suzetrigine for pain relief after knee replacement
This trial tests whether suzetrigine can reduce opioid use after a total knee replacement compared with placebo.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.